Workflow
Hangzhou Seck Intelligent Technology (300897)
icon
Search documents
山科智能:截至2026年1月30日公司股东人数7269户
Zheng Quan Ri Bao Wang· 2026-02-03 06:45
证券日报网讯2月3日,山科智能(300897)在互动平台回答投资者提问时表示,截至2026年1月30日的 公司股东人数为7269户。 ...
股海导航_2026年1月30日_沪深股市公告与交易提示
Xin Lang Cai Jing· 2026-01-29 23:15
专题:交易提示 炒股就看金麒麟分析师研报,权威,专业,及时,全面,助您挖掘潜力主题机会! 【停牌】 002231 *ST奥维(维权) 300666 江丰电子 300344 *ST立方(维权) 【复牌】 *ST奥维:收到终止上市事先告知书股票于1月30日起停牌 无 【品大事】 美年健康:拟参与棒杰股份预重整 美年健康(002044)公告,公司拟报名参与浙江棒杰控股集团股份有限公司(简称"棒杰股份")重整投 资人的公开招募,并指定下属全资子公司美年大健康为重整受让主体取得棒杰股份的控制权,成为棒杰 股份重整完成后的控股股东。是否具有参与资格以及最终能否成为重整投资人尚存在不确定性。 白银有色(维权):公司黄金、白银产品的收入占总营业收入比重较低 白银有色(601212)发布股票交易异常波动及严重异常波动公告称,公司黄金、白银产品的收入占总营 业收入的比重较低。2025年上半年,公司营业收入445.59亿元,销售黄金产品收入83.18亿元,占公司营 业收入的比重18.67%,销售白银产品收入20.23亿元,占公司营业收入的比重4.54%。 天顺风能:决定对六家全资子公司实施长期停产安排 天顺风能(002531)公告 ...
晚间公告|1月29日这些公告有看头
Di Yi Cai Jing· 2026-01-29 10:34
Group 1 - Meinian Health plans to participate in the restructuring of Zhejiang Bangjie Holdings, aiming to become the controlling shareholder after the completion of the restructuring [3] - Baiyin Nonferrous Metals reported that the revenue from gold and silver products accounted for a low proportion of total operating income, with gold sales contributing 18.67% and silver sales 4.54% in the first half of 2025 [4] - Tiens Wind Power decided to implement a long-term production suspension for six wholly-owned subsidiaries to optimize resource allocation and focus on core businesses [5] Group 2 - Tongling Nonferrous Metals indicated significant uncertainty in the price fluctuations of its main products, with a low self-sufficiency rate for copper concentrate posing supply stability risks [6] - *ST Aowei received a notice of termination of listing due to its market capitalization falling below 500 million yuan for twenty consecutive trading days [7] - Foton Motor expects a net profit increase of approximately 1551% year-on-year for 2025, driven by sales growth in new energy vehicles and overseas markets [9] Group 3 - Beimo High-tech anticipates a net profit increase of 1076.16% to 1261.87% for 2025, supported by cost control and reduced credit impairment losses [10] - Zhongke Sanhuan forecasts a net profit growth of 566.23% to 899.35% for 2025, attributed to technological innovation and improved operational efficiency [12] - Wancheng Group expects a net profit increase of 222.38% to 266.94% for 2025, driven by growth in its retail business and improved sales margins [13] Group 4 - Huayi Technology anticipates a net profit increase of 191.52% to 330.34% for 2025, benefiting from product optimization and cost reduction measures [14] - Nanmo Biology expects a net profit growth of 269.49% to 423.44% for 2025, supported by increased revenue in the biopharmaceutical sector and improved cost control [15] - Baiao Saitu forecasts a net profit increase of 384.26% to 443.88% for 2025, driven by expansion in overseas markets and recovery in the domestic biopharmaceutical industry [16] Group 5 - Hailanxin expects a net profit increase of 387.47% to 631.2% for 2025, supported by advancements in technology and increased market share in marine observation [17] - Panjiang Co. anticipates a net profit growth of 205.3% to 264.83% for 2025, driven by increased coal production and reduced costs [18] - Huaguang New Materials expects a net profit increase of 104.67% to 141.88% for 2025, with significant growth in the electronic sector [20] Group 6 - Guo Sheng Securities forecasts a net profit increase of 25.44% to 67.25% for 2025, supported by active capital market participation and growth in various business segments [25] - Shengyi Technology expects a net profit growth of 87% to 98% for 2025, driven by increased sales of copper-clad laminates [26] - Sifutian anticipates a net loss of 30 million to 45 million yuan for 2025, although this represents a significant reduction in losses compared to the previous year [27] Group 7 - Maanshan Steel expects a net loss of 1.9 billion to 2.5 billion yuan for 2025, with a substantial reduction in losses compared to the previous year [28] - Shennong Seed Industry forecasts a net profit of 90 million to 120 million yuan for 2025, marking a turnaround from previous losses [30] - Jifeng Co. anticipates a net profit of 410 million to 495 million yuan for 2025, achieving a turnaround from losses [31]
1月29日晚间重要公告一览
Xi Niu Cai Jing· 2026-01-29 10:13
Earnings Forecasts - Shengyi Electronics expects a net profit of 1.431 billion to 1.513 billion yuan in 2025, an increase of 331.03% to 355.88% year-on-year [1] - Tigermed anticipates a net profit of 830 million to 1.23 billion yuan in 2025, representing a growth of 105% to 204% year-on-year [2] - Shunbo Alloy forecasts a net profit of 210 million to 270 million yuan in 2025, with an increase of 222.96% to 315.23% year-on-year [3] - Jinkong Electric expects a net profit of 155 million to 195 million yuan in 2025, reflecting a growth of 383.21% to 507.9% year-on-year [9] - Baiao Saitu anticipates a net profit of 162 million to 182 million yuan in 2025, with a year-on-year increase of 384.26% to 443.88% [18] - Panjiang Co. expects a net profit of 318 million to 380 million yuan in 2025, representing a growth of 205.30% to 264.83% year-on-year [38] Loss Forecasts - Liaoning Energy predicts a net loss of 273 million to 410 million yuan in 2025, compared to a profit of 202 million yuan in the previous year [5] - Anbotong anticipates a net loss of 114 million to 165 million yuan in 2025, with a revenue decrease of 19.65% to 27.25% [7] - Wantai Bio forecasts a net loss of 330 million to 410 million yuan in 2025, compared to a profit of 106 million yuan in the previous year [12] - Xingyun Co. expects a net loss of 155 million to 230 million yuan in 2025, compared to a loss of 82.44 million yuan in the previous year [20] - Huaxing Co. anticipates a net loss of 800 million to 1.2 billion yuan in 2025, with a reduction in loss compared to 1.67 billion yuan in the previous year [46] New Product Approvals - Hengrui Medicine received acceptance for a new indication application for its innovative drug, combining Carrelizumab and Apatinib for treating unresectable liver cancer [4] - Tianen Kang's subsidiary received a drug registration acceptance notice for Lidocaine and Prilocaine aerosol [31] - Lisheng Pharmaceutical announced that its Aminophylline tablets passed the consistency evaluation for generic drugs [40] Share Buyback Plans - Hengyuan Coal Power plans to repurchase shares with a total amount not less than 200 million yuan and not exceeding 250 million yuan [13] Contract Wins - China Communication Signal Co. won contracts totaling approximately 5.26 billion yuan for 21 important projects in the railway and urban rail transit markets [37]
山科智能(300897) - 2025 Q4 - 年度业绩预告
2026-01-29 09:12
证券代码:300897 证券简称:山科智能 公告编号:2026-004 杭州山科智能科技股份有限公司 | 项 目 | | | 本报告期 | | 上年同期 | | --- | --- | --- | --- | --- | --- | | 归属于上市公司股 | 比上年同期 | 1,500 | ~ | 2,100 | 8,145.29 | | 东的净利润 | 下降 | 81.58% | ~ | 74.22% | | | 扣除非经常性损益 | 比上年同期 | 1,200 | ~ | 1,700 | 7,637.86 | | 后的净利润 | 下降 | 84.29% | ~ | 77.74% | | 二、与会计师事务所沟通情况 本期业绩预告相关数据是公司财务部门初步测算的结果,未经会计师事务所审计。公 司已就本次业绩预告有关事项与年审会计师事务所进行了预沟通,公司与年审会计师事务 所在业绩预告方面不存在分歧情况。 三、业绩变动原因说明 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记载、误 导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间:2025 年 1 月 1 ...
山科智能(300897) - 关于收到中标通知书的公告
2026-01-29 07:42
证券代码:300897 证券简称:山科智能 公告编号:2026-005 杭州山科智能科技股份有限公司 关于收到中标通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 近日,杭州山科智能科技股份有限公司(以下简称"公司")收到福建省水 利投资开发集团有限公司的两份《中标通知书》,确认公司为"2025 年-2027 年度大宗物资集中采购项目超声波远传水表设备采购"和"2025 年-2027 年度大 宗物资集中采购项目无磁远传水表设备采购"的中标人,现将具体中标情况公告 如下: 一、中标项目概况 (一)福建省水利投资开发集团有限公司 2025 年-2027 年度大宗物资集中 采购项目超声波远传水表设备采购 1、招标人:福建省水利投资开发集团有限公司; 2、招标方式:公开招标; 3、中标单位:杭州山科智能科技股份有限公司; 4、中标价:人民币 10,466,150.83 元(大写:壹仟零肆拾陆万陆仟壹佰伍 拾元捌角叁分) (二)福建省水利投资开发集团有限公司 2025 年-2027 年度大宗物资集中 采购项目无磁远传水表设备采购 1、招标人:福建省水利投资开 ...
山科智能1月28日获融资买入457.92万元,融资余额1.13亿元
Xin Lang Zheng Quan· 2026-01-29 01:24
截至1月20日,山科智能股东户数7211.00,较上期减少4.81%;人均流通股12123股,较上期增加 5.05%。2025年1月-9月,山科智能实现营业收入3.80亿元,同比减少22.56%;归母净利润2614.98万元, 同比减少59.34%。 分红方面,山科智能A股上市后累计派现2.16亿元。近三年,累计派现1.27亿元。 责任编辑:小浪快报 融资方面,山科智能当日融资买入457.92万元。当前融资余额1.13亿元,占流通市值的2.96%,融资余 额超过近一年90%分位水平,处于高位。 融券方面,山科智能1月28日融券偿还0.00股,融券卖出0.00股,按当日收盘价计算,卖出金额0.00元; 融券余量5400.00股,融券余额14.70万元,超过近一年90%分位水平,处于高位。 资料显示,杭州山科智能科技股份有限公司位于浙江省杭州市余杭区瓶窑镇蒿山路47号山科智慧园B 座,成立日期1999年11月8日,上市日期2020年9月28日,公司主营业务涉及各类智能远传水表计量传感 器及整表、水务管网现场控制机以及后端的采集系统的研发、生产、销售及服务。主营业务收入构成 为:智能远传水表及计量传感器79.12% ...
公告精选︱三生国健:2025年度预计净利润29.00亿元左右 同比涨幅约311.35%;东方日升:光伏产品未直接向商业航天卫星公司供货
Ge Long Hui· 2026-01-27 00:32
| | | 1月26日重要公告精选 | | --- | --- | --- | | 类型 | 公司 | 主要内容 | | 热点 | 德龙汇能 | 不涉及芯片及相关业务 | | | 东方日升 | 光伏产品未直接向商业航天卫星公司供货 | | 项目投资 | 川环科技 | 拟约11亿元投建川环科技(华东)智造总部基地 | | 合同中标 | 山科智能 | 中标智慧水务平台开发项目 | | 业绩换告 | 均胜电子 | 预计2025年归母净利润约13.5亿元,同比增长40.56% | | 股权转让 | 紫金矿业 | 拟收购AlliedGold Corporation 100%股权 | | 回购 | 吉祥航空 | 已实际回购1.67%公司股份 | | 增减持 | 开普检测 | 董事长姚致清拟减持不超过3%股份 | | 其他 | 浙海德曼 | 拟定增募资不超15.17亿元 | | | 特宝生物 | 拟发行可转债募资不超15.33亿元 片脂磨汇 | 【热点】 浙文互联(600986.SH):旗下"派智"数字人业务产生的收入和利润占公司营业收入和净利润的比例均不到 1%,占比较小 东方日升(300118.SZ):光伏产品未直接向 ...
山科智能:关于中标智慧水务平台开发项目的公告
Zheng Quan Ri Bao· 2026-01-26 14:20
证券日报网讯 1月26日,山科智能发布公告称,近日,公司收到福建省水利水电工程局有限公司的《中 标通知书》,确认公司为"清流县城乡供水一体化建设项目二期设计采购施工总承包智慧水务平台开发 技术服务项目"的中标人。 (文章来源:证券日报) ...
山科智能:收到智慧水务平台开发项目中标通知书
Sou Hu Cai Jing· 2026-01-26 11:30
免责声明:本文内容与数据仅供参考,不构成投资建议,使用前请核实。据此操作,风险自担。 每经AI快讯,山科智能1月26日晚间发布公告称,近日,杭州山科智能科技股份有限公司(以下简称"公 司")收到福建省水利水电工程局有限公司的《中标通知书》,确认公司为"清流县城乡供水一体化建设 项目二期设计采购施工总承包智慧水务平台开发技术服务项目"的中标人。中标金额1210.95万元。 每日经济新闻 每经头条(nbdtoutiao)——国际金价冲破5000美元!7年涨了280%,什么时候才见顶?专家:关键还 看美元,重点关注国际货币体系、降息和科技革命 (记者 曾健辉) ...